📢 Join us for CUA Highlights of ASCO GU 2024! Register for free: cua.org/event/22644 ASCO #GUASCO #ASCO Jeffrey Graham

A historic day for #kidneycancer & the field of #oncology as a whole at ASCO #GU24. Toni Choueiri, MD Dana-Farber & colleagues present the 1st randomized phase 3 study to show a survival advantage w adjuvant PD1 inhibition, reinforcing this approach as SOC. Proud of his tireless

Great point by Tom Powles! Quality of life for #kidneycancer pts is more than assessing symptoms and AEs during clinical trials. We need tools to characterize and define the disease burden that pts experience throughout the course of their disease.

Delighted to announce that our new paper has been published European Urology! Brain mets were found in 389/4799 (8.1%) mRCC pts and intensive systemic/focal therapies were associated with better prognosis. Special thanks to Toni Choueiri, MD Daniel Heng and other collaborators IMDC

Busy week of #oncologyeducation presentation of GU asco bladder cancer highlights at CUA Canadian Urological Association and oncology education GU ASCO 2024 roundtable key abstract highlights OncologyEducation. Thank you for these opportunities to teach about topics I love.

Summary of clinical trials in advanced non-clear cell RCC #GU24. The studies are small & pathology mixed ‘the moons of Jupiter’. The focus on PD1 & VEGF was not driven by the biology. Large randomised trials such as SAMETA exploring MET in selected papillary seems like progress.

King Charles’s open communications about his cancer diagnosis has people talking. Healthy discussions about the rising incidence of cancers, research efforts, and advent of novel therapeutics are happening. Here is a nice easy read: bbc.com/future/article…

Watch our expert discussions on notable trials presented at the ASCO GU Symposium around bladder, kidney and prostate cancer. ow.ly/8Bq650QAgnY #AMBASSADOR #BRCAAway #CheckMate914 #CONTACT2 #EV302 #GETUG-AFU18 #Keynote564 #SCNivolumab #GUCancer #MedOnc #OncEd #Oncology

🔔 Our #GUCancers Symposium Roundtable Discussions are now available for on-demand viewing. Watch as Nazanin Fallah-Rad, Sebastien Hotte & Maria Jiang analyze some of the most notable trials presented around bladder, kidney & prostate cancer: ow.ly/BIfs50QBVuo #MedOnc #OncEd

Genetics and genomics, two words we hear together more and more. They seem to be used interchangeably but are there any differences? Dr. Raymond Kim, medical geneticist, accepted our invitation for a more in-depth look on the subject zoom.us/webinar/regist… #kidneycancer

At #JSMO with 3 controversies from ASCOGU 1) The -ve OS adjuvant pembro data in UC questions this approach more broadly. Censoring ++ on KM curve though. 2) More data needed to prove atezo is active with cabo in CRPC. 3)Ipi/nivo looks as good as anything else in good risk M1 RCC

Is extending life by weeks worth the toll some cancer drugs take? Doctors push for 'common-sense oncology' cbc.ca/news/health/ca…

We’re excited to share some of the esteemed faculty presenting at our upcoming Best of #ASCO GU & GI Cancers Conference. Maria Jiang Nazanin Fallah-Rad Jeffrey Graham Sebastien Hotte #DrElieKassouf Aly-Khan Lalani Full agenda & registration here: ow.ly/ToGm50QXG8j #MedOnc

2 in 5 Canadians are expected to be diagnosed with cancer in their lifetime. Approximately 1 in 4 Canadians is expected to die of the disease. Often the question is “Why me?”. The answer is often “It’s nothing you did. It’s simply chance.” #cancer

Back to basics! Canadian Urological Association looking forward to teaching a basic science of oncology course to Canadian PGY 1-2 urology residents about chemo, VEGF inhibitors, radio-pharmaceuticals, and immune check point inhibition commonly used in treatment of GU cancers.

JOIN US FOR THIS EVENT! Groundbreaking advancements in the treatment of patients with advanced urothelial carcinoma / Tuesday September 10, 2024 / 19:00 - 20:00 ET REGISTRATION IS FREE >>> cua.org/event/29711

I had a terrific experience participating in an observership program at 12 de Octubre University Hospital. I particularly enjoyed being educated about access to oncology therapeutics in various parts of the world. #kidneycancer #bladdercancer #prostatecancer #spain

Thank you for the invitation! It’s always a pleasure. There were amazing speakers this year including Dr. Chris Booth: common sense oncology. These sessions help me keep up to date as well.

You can’t take our country — and you can’t take our game.

Productive session with visiting Dr. Saleh Ramy Saleh, MD, MSc from McGill university, reviewing approach to systemic therapy for advanced RCC. What’s in the future: Dosing TKI’s wisely in combo with IO frontline, SC IO, RLT’s, moving HIF-2alpha’s forward in trials. Great debates.